MRX 952
Alternative Names: HydroPlex™ MRX-952; MRX-952; SN38 NanoparticlesLatest Information Update: 14 May 2007
At a glance
- Originator ImaRx Therapeutics
- Class
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 15 Jun 2005 Preclinical trials in Cancer in USA (unspecified route)
- 27 Sep 2004 Suspended - Preclinical for Cancer in USA (unspecified route)
- 05 Jul 2004 This compound is still in active development - BIO 2004 Annual International Convention (BIO-2004)